JP2008526989A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526989A5
JP2008526989A5 JP2007551410A JP2007551410A JP2008526989A5 JP 2008526989 A5 JP2008526989 A5 JP 2008526989A5 JP 2007551410 A JP2007551410 A JP 2007551410A JP 2007551410 A JP2007551410 A JP 2007551410A JP 2008526989 A5 JP2008526989 A5 JP 2008526989A5
Authority
JP
Japan
Prior art keywords
substituted
disease
compound according
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007551410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526989A (ja
JP5475949B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/001275 external-priority patent/WO2006076595A1/en
Publication of JP2008526989A publication Critical patent/JP2008526989A/ja
Publication of JP2008526989A5 publication Critical patent/JP2008526989A5/ja
Application granted granted Critical
Publication of JP5475949B2 publication Critical patent/JP5475949B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007551410A 2005-01-13 2006-01-13 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法 Expired - Lifetime JP5475949B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64379605P 2005-01-13 2005-01-13
US60/643,796 2005-01-13
US70998005P 2005-08-19 2005-08-19
US60/709,980 2005-08-19
PCT/US2006/001275 WO2006076595A1 (en) 2005-01-13 2006-01-13 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013151233A Division JP5841569B2 (ja) 2005-01-13 2013-07-22 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法

Publications (3)

Publication Number Publication Date
JP2008526989A JP2008526989A (ja) 2008-07-24
JP2008526989A5 true JP2008526989A5 (cg-RX-API-DMAC7.html) 2009-02-26
JP5475949B2 JP5475949B2 (ja) 2014-04-16

Family

ID=36228639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007551410A Expired - Lifetime JP5475949B2 (ja) 2005-01-13 2006-01-13 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2013151233A Expired - Lifetime JP5841569B2 (ja) 2005-01-13 2013-07-22 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2015187617A Pending JP2016065057A (ja) 2005-01-13 2015-09-25 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013151233A Expired - Lifetime JP5841569B2 (ja) 2005-01-13 2013-07-22 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2015187617A Pending JP2016065057A (ja) 2005-01-13 2015-09-25 ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法

Country Status (22)

Country Link
US (2) US7723340B2 (cg-RX-API-DMAC7.html)
EP (3) EP2289893B1 (cg-RX-API-DMAC7.html)
JP (3) JP5475949B2 (cg-RX-API-DMAC7.html)
KR (1) KR101294830B1 (cg-RX-API-DMAC7.html)
CN (1) CN103087066A (cg-RX-API-DMAC7.html)
AT (1) ATE435227T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006204792B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0606702A2 (cg-RX-API-DMAC7.html)
CA (1) CA2595182C (cg-RX-API-DMAC7.html)
CY (1) CY1109306T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006007541D1 (cg-RX-API-DMAC7.html)
DK (1) DK1838710T3 (cg-RX-API-DMAC7.html)
ES (3) ES2497540T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090383T1 (cg-RX-API-DMAC7.html)
IL (2) IL184550A (cg-RX-API-DMAC7.html)
MX (1) MX2007008485A (cg-RX-API-DMAC7.html)
NZ (1) NZ556654A (cg-RX-API-DMAC7.html)
PL (1) PL1838710T3 (cg-RX-API-DMAC7.html)
PT (1) PT1838710E (cg-RX-API-DMAC7.html)
RS (1) RS51176B (cg-RX-API-DMAC7.html)
SI (1) SI1838710T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006076595A1 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
GB0526042D0 (en) * 2005-12-21 2006-02-01 Syngenta Participations Ag Chemical compounds
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2007309167A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as PKC-theta inhibitors
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011071491A1 (en) * 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
CN102260263A (zh) * 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
TWI410425B (zh) 2010-12-03 2013-10-01 Lilly Co Eli 唑并[5,4-b]吡啶-5-基化合物
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN104098563A (zh) * 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
DK3204386T3 (da) * 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
US10576085B2 (en) * 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX379439B (es) 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.
ES2926149T3 (es) * 2016-06-02 2022-10-24 Celgene Corp Agentes antipalúdicos animales y humanos
US10010555B2 (en) 2016-06-02 2018-07-03 Celgene Corporation Animal and human anti-trypanosomonal and anti-leishmania agents
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
EP3692041A1 (en) 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
CN109694395B (zh) * 2017-10-23 2020-08-28 武汉惠康达科技有限公司 一种用于缺血再灌注损伤的化合物及其制备方法
CN107892691B (zh) * 2017-12-19 2020-04-28 西安交通大学 2,8,9-三取代-9h-嘌呤类化合物及其盐和应用
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
US20230099367A1 (en) * 2019-04-16 2023-03-30 Versitech Limited Purmorphamine as a small compound positive allosteric modulator of secretin receptor for the treatment of hypertension
EP3772513A1 (en) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
CN112430632B (zh) * 2020-11-18 2022-09-13 上海合全药物研发有限公司 2-((反式)-4-氨基环己烷基)异丙醇的制备方法
CN113582995B (zh) * 2021-08-17 2022-08-16 西安交通大学 9-位含有丙烯酰氨基片段的-9h-嘌呤类化合物及其盐和应用
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023133354A2 (en) * 2022-01-10 2023-07-13 Southern Research Institute Development of potential antidotes for arsenicals
CN117430614B (zh) * 2023-12-20 2024-03-08 首都医科大学 一种异喹啉类衍生物及其合成方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US643796A (en) 1899-08-03 1900-02-20 William H Hunter Washing-machine.
US709980A (en) 1901-02-04 1902-09-30 Hubert Gilljam Carding-machine.
IL78643A0 (en) * 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
WO1999007705A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
TR200601782T2 (tr) 1999-11-12 2006-09-21 Pharmasset Ltd. 2'-Deoksi-L-Nükleositlerin sentezi.
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
JP2005504727A (ja) 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7256196B1 (en) 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith

Similar Documents

Publication Publication Date Title
CA2595182A1 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ES2638517T3 (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
CN104487441B (zh) 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
RU98123097A (ru) Карбоксамиды бензофурана и их терапевтическое применение
TWI699359B (zh) 4h-吡咯[3,2-c]吡啶-4-酮衍生物
ES2878030T3 (es) Inhibidores de tirosina cinasa
CN1285833A (zh) 嘌呤衍生物以及含有其作为有效成分的药物
CN100595199C (zh) 改变药物晶体形成的方法
ES2539256T3 (es) Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
JP2024513494A5 (cg-RX-API-DMAC7.html)
JP2009534421A5 (cg-RX-API-DMAC7.html)
JP2021523159A5 (cg-RX-API-DMAC7.html)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
CA2537127A1 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
JP2009524691A5 (cg-RX-API-DMAC7.html)
JP2002516314A5 (cg-RX-API-DMAC7.html)
RS56807B1 (sr) Jedinjenja aminopirimidinila kao jak inhibitori
CA2952307A1 (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CA2545092A1 (en) Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
JP2005539045A5 (cg-RX-API-DMAC7.html)
JP2015532289A5 (cg-RX-API-DMAC7.html)
EA018995B1 (ru) Производные карбаматов алкилтиазолов, их получение и их применение в терапии
JP2016028076A5 (cg-RX-API-DMAC7.html)
RU2006120486A (ru) Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны
KR20200011388A (ko) Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물